Evidence map›Paper›PMID 30108645›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2018

ETAS®50 Attenuates Ultraviolet-B-Induced Interleukin-6 Expression by Suppressing Akt Phosphorylation in Normal Human Dermal Fibroblasts.

Ken Shirato, Tomoko Koda, Jun Takanari, Junetsu Ogasawara, Takuya Sakurai, Hideki Ohno, Takako Kizaki

Abstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. ETASPharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Standardized Extract ofMolecules (Basel, Switzerland) · 2021
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ken ShiratoDepartment of Molecular Predictive Medicine and Sport Science, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan.ORCID 0000-0002-3151-9417
Tomoko KodaFaculty of Nursing, Tokyo Healthcare University, 2-5-1 Higashigaoka, Meguro, Tokyo 152-8558, Japan.
Jun TakanariAmino Up Chemical Co. Ltd., 363-32 Shin-ei, Kiyota, Sapporo, Hokkaido 004-0839, Japan.
Junetsu OgasawaraDepartment of Health Science, Asahikawa Medical University, 2-1-1-1 Midorigaoka-Higashi, Asahikawa, Hokkaido 078-8510, Japan.ORCID 0000-0003-1761-9806
Takuya SakuraiDepartment of Molecular Predictive Medicine and Sport Science, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan.ORCID 0000-0003-0135-8525
Hideki OhnoSocial Medical Corporation, The Yamatokai Foundation, 1-13-12 Nangai, Higashiyamato, Tokyo 207-0014, Japan.
Takako KizakiDepartment of Molecular Predictive Medicine and Sport Science, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan.ORCID 0000-0001-9222-8771

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We recently reported that ETAS 50, a standardized extract from the

Identifiers

PMID30108645
PMCPMC6077605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.